Elutia (ELUT) Planet MicroCap Showcase: VEGAS 2025 summary

Mission and market positioning

• Focus on humanizing medicine by prioritizing biologic implants with active pharmaceutical agents over metals and synthetics.

• Targeting the $60 billion biomaterials market with drug-eluting biologics, starting with the newly approved EluPro envelope for pacemakers and defibrillators.

• Leadership team has a strong track record in regenerative medicine and successful company exits.

Product innovation and clinical advantages

• EluPro combines a regenerative biologic matrix with antibiotics, reducing foreign body response and promoting tissue integration.

• Designed to prevent pacemaker complications such as migration, erosion, and infection, which occur in 7%-11% of cases.

• Only one other antibiotic-eluting envelope exists, creating a favorable competitive landscape.

Commercial traction and partnerships

• EluPro pilot launch in Q4 showed strong initial traction, with same center sales up 65%.

• Product is now active in over 100 institutions, with 10-12 new VAC approvals monthly and coverage by seven major GPOs.

• Distribution partnership with Boston Scientific adds 900 reps, accelerating hospital access and sales.